Simcere Pharmaceutical Group Ltd - Company Profile
Powered by 
All the data and insights you need on Simcere Pharmaceutical Group Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Simcere Pharmaceutical Group Ltd Strategy Report
- Understand Simcere Pharmaceutical Group Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Simcere Pharmaceutical Group Ltd (Simcere) is a pharmaceutical company that discovers, develops, and markets branded generic and prescription pharmaceutical products. The company offers services in therapeutic areas such as anti-tumor, anti-infection, central nervous, cardiovascular, skeletal muscle and others. Simcere’s products are used for the treatment of oncology, infectious diseases, neurology, anti-inflammation and also cardiovascular diseases. The company conducts research and development focused on low-end generics and APIs for innovative medicines. Simcere is headquartered in Nanjing, Jiangsu, China
Headquarters
China
Address
No. 699-18, Xuanwu Avenue, Xuanwu District, Nanjing, Jiangsu
Website
www.simcere.com
No of Employees
7,027
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
2096 (HKG)
Revenue (2022)
$934.3M
4.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-23.2%
(2022 vs 2021)
Market Cap*
$1.9B
Net Profit Margin (2022)
XYZ
-26.5%
(2022 vs 2021)
* As of and is in US$
Simcere Pharmaceutical Group Ltd premium industry data and analytics
Products and Services
| Services | Brands |
|---|---|
| Anti-Tumor | LOWVO |
| Recombinant Human Endostatin Injection | Ebdostar |
| Nedaplatin for Injection | JEPASO |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In March, the company received approval from the U.S. Food and Drug Administration for a new drug application of SIM0500, a humanized GPRC5D-BCMA-CD3 tri-specific antibody to treat patients with relapsed or refractory multiple myeloma. |
| 2024 | Contracts/Agreements | In January, the company entered into a partnership with Stanford University to start research in the field of the nervous system and form innovative treatments for Parkinson’s patients. |
| 2023 | Contracts/Agreements | In November, the company entered into an agreement with Connect Biopharma Holdings Limited to develop and commercialize in Greater China. |
Competitor Comparison
| Key Parameters | Simcere Pharmaceutical Group Ltd | North China Pharmaceutical Co Ltd | Jiangsu Nhwa Pharmaceutical Co Ltd | Nanjing King-friend Biochemical Pharmaceutical, No.1-16 Xuefu Road, Nanjing, Jiangsu, China | Qilu Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | |
| City | Nanjing | Shijiazhuang | Xuzhou | - | Jinan |
| State/Province | Jiangsu | Hebei | Jiangsu | - | Shandong |
| No. of Employees | 7,027 | 10,159 | 5,394 | - | 15,000 |
| Entity Type | Public | Public | Public | Facility | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jinsheng Ren | Chairman; Chief Executive Officer | Executive Board | 2004 | 60 |
| Yushan Wan | Director; Secretary - Joint; Chief Financial Officer | Executive Board | 2017 | 52 |
| Wang Xi | Director; Vice President | Executive Board | 2023 | 40 |
| Tang Renhong | Director | Executive Board | 2022 | 43 |
| Zhou Gaobo | Chief Investment Officer | Senior Management | 2022 | 44 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer